Revvity (RVTY) Stock Price, News & Analysis

Company Overview

Revvity, Inc., formerly known as PerkinElmer, is a global provider of life sciences and diagnostics solutions, headquartered in Waltham, Massachusetts. The company focuses on supplying a comprehensive portfolio of instruments, reagents, software and services to support research, drug discovery, genetic screening, and precision diagnostics. Its offerings span from high-throughput screening platforms and imaging systems to immunoassays and molecular diagnostics kits, designed to meet the rigorous requirements of pharmaceutical, biotechnology and clinical laboratory customers.

In the life sciences segment, Revvity’s products facilitate cell analysis, genomic research, proteomics and biomarker discovery. The diagnostics segment provides immunodiagnostics, clinical chemistry and infectious disease testing solutions for hospitals, reference laboratories and public health institutions. The company also serves applied and reference markets through environmental testing, food safety and industrial quality control applications, delivering analytical instruments, consumables and informatics tools that help clients ensure compliance and enhance operational efficiency.

With roots dating back to the founding of Perkin-Elmer in 1937, Revvity has grown through strategic acquisitions and continuous innovation. Over the decades, the company has integrated technologies such as advanced mass spectrometry, confocal microscopy and automated liquid handling systems, expanding its global footprint and R&D capabilities. In October 2023, PerkinElmer officially rebranded as Revvity to reflect its renewed focus on accelerating scientific and clinical breakthroughs.

Revvity operates in more than 150 countries, with major research and manufacturing centers in North America, Europe and Asia-Pacific. Under the leadership of President and CEO Prahlad Singh, the company emphasizes customer collaboration, sustainability and long-term growth. Revvity’s multidisciplinary team of scientists, engineers and healthcare professionals works to deliver solutions that address complex biological challenges, aiming to improve patient outcomes and advance scientific discovery worldwide.

Key Stats

• Today's Range: $100.41 to $101.80
• 50-Day Range: $89.26 to $102.47
• 52-Week Range: $87.70 to $129.50
• Volume: 676,357 shs
• Average Volume: 976,872 shs
• Market Capitalization: $11.96 billion
• P/E Ratio: 43.19
• Dividend Yield: 0.28%
• Price Target: $123.07
• Consensus Rating: Moderate Buy

Revvity Stock Analysis - MarketRank™

Revvity scored higher than 56% of companies evaluated by MarketBeat, and ranked 410th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Revvity has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Revvity has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.55%

Earnings Growth

Earnings for Revvity are expected to grow by 12.55% in the coming year, from $4.94 to $5.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revvity is 43.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revvity is 43.19, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.13.

Price to Earnings Growth Ratio

Revvity has a PEG Ratio of 2.58. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Revvity has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.06% of the float of Revvity has been sold short.

Short Interest Ratio / Days to Cover

Revvity has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Revvity has recently increased by 5.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Revvity has a dividend yield of 0.27%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Revvity does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Revvity is 11.91%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Revvity will have a dividend payout ratio of 5.04% next year. This indicates that Revvity will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.06% of the float of Revvity has been sold short.

Short Interest Ratio / Days to Cover

Revvity has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Revvity has recently increased by 5.51%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.97

News Sentiment

Revvity has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Revvity this week, compared to 9 articles on an average week.

Search Interest

Only 3 people have searched for RVTY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Revvity to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revvity insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.68% of the stock of Revvity is held by insiders.

Percentage Held by Institutions

86.65% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RVTY Stock Analysis - Frequently Asked Questions

How have RVTY shares performed this year?

Revvity's stock was trading at $111.61 on January 1st, 2025. Since then, RVTY shares have decreased by 9.1% and is now trading at $101.4940.

How were Revvity's earnings last quarter?

Revvity Inc. (NYSE:RVTY) posted its quarterly earnings data on Monday, April, 28th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.05. The company's revenue was up 2.3% on a year-over-year basis.
Read the conference call transcript.

Is Revvity doing a stock buyback?

Revvity's board initiated a share repurchase program on Monday, November 4th 2024, which allows the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 6.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board believes its shares are undervalued.

Who are Revvity's major shareholders?

Top institutional shareholders of Revvity include Family Legacy Financial Solutions LLC (0.05%), Czech National Bank (0.02%), IFM Investors Pty Ltd (0.02%) and Swedbank AB (0.01%). Insiders that own company stock include Prahlad R Singh, Joel S Goldberg and Tajinder S Vohra.
View institutional ownership trends.

How do I buy shares of Revvity?

Shares of RVTY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Revvity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Ex-Dividend for 5/9 Dividend: 4/17/2025
• Record date for 5/9 Dividend: 4/18/2025
• Last Earnings: 4/28/2025
• Dividend Payable: 5/09/2025
• Today: 7/12/2025
• Record date for 8/8 Dividend: 7/18/2025
• Ex-Dividend for 8/8 Dividend: 7/18/2025
• Next Earnings (Estimated): 7/28/2025
• Dividend Payable: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NYSE:RVTY
• CIK: 31791
• Web: www.perkinelmer.com
• Phone: (781) 663-6900
• Fax: 781-663-5985
• Employees: 11,000
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Revvity: $123.07
• High Price Target: $145.00
• Low Price Target: $100.00
• Potential Upside/Downside: +21.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.35
• Trailing P/E Ratio: 43.19
• Forward P/E Ratio: 20.55
• P/E Growth: 2.58
• Net Income: $270.39 million
• Net Margins: 10.35%
• Pretax Margin: 12.06%
• Return on Equity: 7.73%
• Return on Assets: 4.72%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 3.58
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $2.76 billion
• Price / Sales: 4.34
• Cash Flow: $8.44 per share
• Price / Cash Flow: 12.02
• Book Value: $63.00 per share
• Price / Book: 1.61

Miscellaneous

• Outstanding Shares: 117,870,000
• Free Float: 117,068,000
• Market Cap: $11.96 billion
• Optionable: Optionable
• Beta: 0.98